title: Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in psoriatic lesions.
abstract: BACKGROUND
  Antithyroid thioureylenes are effective agents in the oral and topical treatment of patients with chronic plaque psoriasis.
  
  
  METHODS
  The effect of oral treatment with 6-n-propyl 2-thiouracil (propylthiouracil, PTU) and 2-mercapto 1-methyl imidazole (methimazole, MMI) on proliferating cell nuclear antigen (PCNA), and p53 protein expression was studied in patients with stable plaque psoriasis.
  
  
  RESULTS
  Following treatment with PTU and MMI, PCNA staining in psoriatic epidermis was significantly decreased. P53 was minimally expressed in untreated lesions, and treatment with PTU and MMI did not enhance p53 expression in the psoriatic lesions.
  
  
  CONCLUSIONS
  Since PCNA is a marker of cellular proliferation and p53 inhibits cellular cycling, some of the beneficial effects of PTU and MMI in psoriasis may depend on the ability of the drugs to impair cellular turnover, perhaps by binding to the triiodothyronine (T3) receptor. These effects may be in addition to the previously described effects of PTU and MMI as immune modulators and free radical scavengers.
authors.affiliation: Department of Medicine, University of California at Irvine, USA.
authors.forename: A N
authors.initials: AN
authors.lastname: Elias
authors.forename: R J
authors.initials: RJ
authors.lastname: Barr
authors.forename: M K
authors.initials: MK
authors.lastname: Rohan
authors.forename: K
authors.initials: K
authors.lastname: Dangaran
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008713:Methimazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D018809:Proliferating Cell Nuclear Antigen / Q000187:drug effects* / Q000235:genetics; D011441:Propylthiouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects* / Q000235:genetics
chemical_list: D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; D008713:Methimazole; D011441:Propylthiouracil